AdBio Partners SAS. (6/18/24). "Press Release: Inserm Transfert and AdBio Partners Launch AndzonBio". Paris.

	Region	France
	Organisation	AdBio Partners SAS (AFB)
	Group	AdBio Partners (Group)
	Organisation 2	Inserm Transfert S.A.
	Group	France (govt)
	Product	venture capital
	Product 2	BIOTECH
	Person	Augé, Pascale (INSERM 201403– CEO of Inserm Transfert before Institut Pasteur + Neurotech + Entomed + AB Science)
	Person 2	Huriez, Alain (Advent France Biotechnology 201704 Managing Partner before Advent Life Sciences + TcLand + Neovacs)

AdBio partners, a leading European early stage Venture Capital firm dedicated to life sciences, and Inserm Transfert, the private company, subsidiary of the French National Institute of Health and Medical Research (Inserm) Europe's leading player in life sciences research, are strengthening their strategic alliance and are announcing the launch of a suite of thematic Biotech Venture Studios: AndzonBio.

To address the pressing demand of the European ecosystem for seed financing in life sciences, AdBio partners and Inserm Transfert launch AndzonBio, a suite of thematic studios to accelerate the industrial development of the most promising academic projects in biotechnology.

"For many years, Inserm Transfert has observed the lack of dedicated structures to de-risk early innovation projects by providing them with the industrial expertise and funding needed to achieve key milestones. Inserm Transfert has been maturing this start-up studio project for a long time. Our high-quality collaboration with the AdBio partners team has now led to the realization of this concept of thematic studios suite with a historical and trusted partner of Inserm Transfert" says Pascale Augé, Chairman of the Executive Board of Inserm Transfert.

This initiative, in line with their strategic partnership (see press release of May 2022), demonstrates the continued dedication of these two leading actors in the European biotech ecosystem to the acceleration of research and development in life sciences, to foster and support breakthrough innovations from academic labs. These thematic studios will leverage the most promising academic projects, by providing them with a dedicated team, as well as financial and industrial resources for early and rapid development. Each studio is designed to transform into a start-up ready to receive seed funding, after a demanding selection process and rigorous validation through a series of decisive experimental milestones.

"AdBio partners is expanding its footprint and taking a bold step towards earlier investment, bridging the gap between academic and seed funding. AdBio thus becomes the first European investment fund to cover the entire spectrum of life sciences seed funding" says Alain Huriez, President and Managing Partner of AdBio partners.

Inserm Transfert is thus strengthening its ability to support innovative upstream projects that will benefit from the scientific expertise of the originating academic research teams, support from drug development experts from the industry, and a substantial financial investment, to get them on track for preclinical and clinical trials.

The first start-up studio AndzonBio1 dedicated to cardiovascular, renal and metabolic diseases will be announced very soon.

About Inserm Transfert

Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm), is responsible for the value creation of innovations at Inserm and its academic partners in human health and promotes long-term technology transfers in line with international best practices. Inserm Transfert SA was founded in 2000. It manages, under a Public Service Management Contract (Délégation de Service Public), the entire promotion and transfer of knowledge emerging from the Inserm research laboratories to the industrial world, from invention disclosure to industrial partnerships and start-up incorporation. Inserm Transfert also offers services relating to setting up and managing national, European and international projects, as well as supporting the technology transfer of clinical research and health data/databases. In 2009, Inserm Transfert and Inserm established an investment fund to finance proofs of concept. In 2005, Inserm Transfert Initiative, a dedicated seed money fund for life sciences, was created. Since 2017 a pathway for pre-entrepreneurship supports researchers/inventors who aspire to become involved in entrepreneurship. In 2022, Inserm Transfert decided to become LPs in AFB Fund II in order to increase the opportunity of investment of seed fund in Inserm Transfert spin-off.

www.inserm-transfert.fr

About AdBio partners

AdBio partners is an AMF-regulated (the French financial market authority) company that invests in a range of sectors within life sciences - specifically in therapeutics-oriented projects. AdBio partners’ unique strategy combines early-stage investments in promising companies and strong entrepreneurial support to strengthen the company’s growth.

Created in 2016, AdBio partners has made 22 European investments in France, Belgium, Spain and
Ireland with two seed-funds. AdBio partners has developed strong relationships within the European innovation ecosystem; as a result, it has attracted international VC syndicates to its portfolio companies. The operational team is composed of investment professionals with extensive corporate experience, combined with strong scientific, medical and operational expertise.

www.adbio.partners

Press and analyst contacts

AdBio Partners
contact@adbio.partners

Inserm Transfert
communication@inserm-transfert.fr

Record changed: 2024-09-12